Antonio Rizzo

Dr. Antonio Rizzo

Humanitas Clinical Institute, 95029 Catania, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
AGAlexandra Giorlandino
Alexandra Giorlandino
ECEnrico Cavallo
Enrico Cavallo
MVMichele Dello Spedale Venti
Michele Dello Spedale Venti
GLGiorgia Leone
Giorgia Leone
ARAntonio Rizzo
Antonio Rizzo
Background: Breast cancer (BC) is a heterogeneous disease made up of clones with different metastatic potential. Intratumoral heterogeneity may cause metastases to show divergent biomarker expression, potentially affecting chemotherapy response. Methods: We investigated the immunohistochemical (IHC) and FISH profile of estrogen receptors (ER), progesterone (PR) receptors, Ki67, and HER2 in a series of BC-matched primary tumors (PTs) and axillary lymph node (ALN) metastases in pre-operative core needle biopsies (CNBs). Phenotypical findings were correlated to morphological features and their clinical implications. Results: Divergent expression between PTs and ALNs was found in 10% of the tumors, often involving multiple biomarkers (12/31, 39%). Most (52%) displayed significant differences in ER and PR staining. HER2 divergences were observed in almost three-quarters of the cases (23/31, 74%), with five (16%) switching from negativity to overexpression/amplification in ALNs. Roughly 90% of disparities reflected significant morphological differences between PTs and ALN metastases. Less than half of the discrepancies (12/31, 39%) modified pre/post-operative treatment options. Conclusions: We observed relevant discrepancies in biomarker expression between PTs and metastatic ALNs in a noteworthy proportion (10%) of preoperative BC CNBs, which were often able to influence therapies. Hence, our data suggest routine preoperative assessment of biomarkers in both PTs and ALNs in cases showing significant morphological differences.

25 January 2023 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
GPGiancarlo Pruneri
Giancarlo Pruneri
DLDaniele Lorenzini
Daniele Lorenzini
Mauro MastropasquaMauro Mastropasqua
Mauro Mastropasqua
GPGiuseppe Perrone
Giuseppe Perrone
ARAntonio Rizzo
Antonio Rizzo
ICIsabella Castellano
Isabella Castellano
Multigenic tests represent an essential tool for the selection of adjuvant therapy in estrogen-positive/HER2-negative (ER + /HER2-) early breast cancer (BC). The workflow of these tests, either if they are externalized or carried out in-house, generates a workload for the pathology laboratories, that is often underestimated and may affect timely therapy initiation. Here, we describe the evolving role of pathology laboratories in using multigenic tests and, more in general, in providing adequate tissue for molecular analyses. Moreover, we propose a “reflex testing” model, in which pathologists, based on pre-specified and shared criteria, are expected to action multigene testing independently of multidisciplinary team discussion in ER + /HER2- BC patients, in order to optimize turnaround time and proper therapy intervention.

1 February 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
LCLeopoldo Costarelli
Leopoldo Costarelli
ARAntonio Rizzo
Antonio Rizzo
MBMarina Bortul
Marina Bortul
FPFrancesca Pietribiasi
Francesca Pietribiasi
MTMario Taffurelli
Mario Taffurelli
LFLucio Fortunato
Lucio Fortunato

28 July 2025 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
FPFrancesco Pepe
Francesco Pepe
Gianluca RussoGianluca Russo
Gianluca Russo
Konstantinos VenetisKonstantinos Venetis
Konstantinos Venetis
CSClaudia Scimone
Claudia Scimone
LPLucia Palumbo
Lucia Palumbo
UMUmberto Malapelle
Umberto Malapelle
To date, ESR1 activating mutations acts as key player to clinically stratify estrogen receptor (ER)+/HER2-advanced breast cancer (BC) patients eligible to novel new generation oral Selective Estrogen Receptor Degraders (SERD) relapsing after first line aromatase inhibitors. Liquid biopsy represents the most useful biological source to detect ESR1 activating mutations in clinical setting, but the lack of standardized pre-analytical and analytical procedures drastically impacts on detection rate of ESR1 mutations in diagnostic specimens. Here, we sought to harmonize technical procedures comparing technical performance of diagnostically available testing strategies on a series of three reference specimens (sample A, B, C) harboring ESR1 p.D538G mutation at different mutant allele fraction (MAF) (5.0 %, 1.0 %, 0.5 %) shared with n = 10 Italian referral institutions. A total of 10 μl of gDNA from each reference sample built to mimic clinically detectable ESR1 molecular alteration (5.0 %, 1.0 %, 0.5 % VAF) was shipped by coordinator institution to each participating group to test p.D538G ESR1 alteration leveraging own routinely available testing strategy. Artificial reference sample was previously validated by the University of Naples Federico II before arranging the shipment. ESR1 exon 10 p.(D538G) hotspot mutation was successfully identified in 90.0 % of samples A, B whereas 8 out of 10 (80.0 %) participating institutions detected sample referenced alteration in sample C. No statistically significant variations were observed between dPCR and NGS based workflows in terms of detectability rate on standard reference samples. A single participating institution (ID#5) failed to detect p.(D538G) ESR1 alteration but supervised procedures by coordinator institution enabled to detect referenced mutation in engineered reference samples set adopting an orthogonal technology (dPCR). In addition, NGS and dPCR platforms displayed a similar technical performance in detecting ESR1 across samples A-C. NGS and dPCR systems may be considered valid technical solutions to target low frequency ESR1 alterations in diagnostic routine samples. Harmonized ring trials are key weapons to standardize analytical and post-analytical procedures optimizing clinical stratification of BC patients

1 June 2025 in Pathologica
Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
ICIsabella Castellano
Isabella Castellano
FCFrancesca Caumo
Francesca Caumo
CCCarmen Criscitiello
Carmen Criscitiello
PFPatrizia Frittelli
Patrizia Frittelli
ARAntonio Rizzo
Antonio Rizzo
Currently, percutaneous sampling via core needle or vacuum-assisted biopsy is the primary choice to guide the management of patients with clinical or screen-detected breast lesions. Preoperative biopsies allow physicians to get pathological diagnoses as well as key prognostic and predictive data about the nature of the investigated process. Namely, adequate biopsy sampling is crucial for assigning lesions to one diagnostic category (B1- B5). Similarly, evaluating morphological (histotype, vascular invasion, necrosis, etc.) and immunohistochemical/molecular features (ER, PR, Ki-67, and HER2) is the key to address the most effective therapies, especially in the neoadjuvant setting. The multidisciplinary team should always discuss the results of percutaneous biopsies, whose global integration with clinical and radiological findings will drive the adoption of specific treatment options, particularly for uncertain (B3) and suspicious/malignant (B4-B5) lesions. In the present work, we report a comprehensive overview of breast percutaneous biopsy techniques, diagnostic categories, and multidisciplinary management based on widely acknowledged evidence of good clinical practice

22 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMStefano Marletta
Stefano Marletta
ECEnrico Cavallo
Enrico Cavallo
MVMichele Dello Spedale Venti
Michele Dello Spedale Venti
GBGiacomo Bonanno
Giacomo Bonanno
FRFabio Romeo
Fabio Romeo
MNMARIANGELA NOVELLO
MARIANGELA NOVELLO
Background and Clinical Significance: Primary pancreatic extramedullary plasmacytomas (EMP) are extremely uncommon, representing less than 0.1% of all pancreatic masses and being far more uncommon than secondary involvement by an underlying multiple myeloma. Case presentation: A 69-year-old male was found with a solitary pancreatic mass. Endoscopic ultrasound (EUS)-guided fine-needle biopsy (FNB) revealed a monoclonal plasmacytic proliferation with molecularly confirmed KRAS (A146V) and BRAF (G469V) mutations. Multidisciplinary assessment ruled out a secondary localization, thus leading to the ultimate diagnosis of primary pancreatic EMP. Conclusions: Reaching a definitive diagnosis of primary pancreatic EMP requires a negative bone marrow biopsy and histological confirmation of the plasma cell nature of the pancreatic process. As for the latter, EUS-FNB may be a pivotal technique to avoid upfront surgical procedures.